Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net loss of US$51.31 million. Earnings per share were a loss of US$0.99, matching analyst expectations. For the first six months of 2026, Axsome Therapeutics reported revenue of US$409.58 million and a net loss of US$115.86 million. Loss per share over this period was US$2.25 on both a basic and diluted basis. See our latest...

Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the story, so the question is whether the present price still leaves enough room for longer term investors to be comfortable. Axsome Therapeutics has returned about 9.4x over the past 5 years, which puts the recent share price firmly at the higher end of its historical range for many...

The FDA has already accepted the company’s application seeking the greenlight for AXS-12.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares rose 2.

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (NASDAQ:AXSM) reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build. The company posted a net loss of $51.3 million, or $0.99 per share, comp

Axsome (AXSM) delivered earnings and revenue surprises of 0.00% and -2.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The benchmark US stock measures were mostly pointing higher before the opening bell Monday as trader

Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +56.52% and +98.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

These innovative biotech companies should reap the benefits of their breakthroughs.

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.

ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here. The Russell 2000 Growth Index increased by 25.6% in the second quarter, marking its third-best quarterly performance in two decades. The rally was fueled by enthusiasm for AI, strength […]

Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls

Jazz Pharmaceuticals (JAZZ) is back in focus after Axsome Therapeutics disclosed an FDA filing for AXS-12 in narcolepsy, highlighting Sunosi’s move from Jazz’s portfolio and refocusing attention on Jazz’s broader sleep-disorder franchise. See our latest analysis for Jazz Pharmaceuticals. Investors have responded to Jazz Pharmaceuticals’ sleep and oncology pipeline story with a 9.1% 1 month share price return and a 42.3% 5 year total shareholder return, while the 1 year total shareholder...

AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.